Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ749844B2 - Solid forms of ttk inhibitor - Google Patents
[go: Go Back, main page]

NZ749844B2 - Solid forms of ttk inhibitor - Google Patents

Solid forms of ttk inhibitor Download PDF

Info

Publication number
NZ749844B2
NZ749844B2 NZ749844A NZ74984417A NZ749844B2 NZ 749844 B2 NZ749844 B2 NZ 749844B2 NZ 749844 A NZ749844 A NZ 749844A NZ 74984417 A NZ74984417 A NZ 74984417A NZ 749844 B2 NZ749844 B2 NZ 749844B2
Authority
NZ
New Zealand
Prior art keywords
crystal
solid forms
formula
ttk inhibitor
compound
Prior art date
Application number
NZ749844A
Other versions
NZ749844A (en
Inventor
Sze Wan Li
Heinz W Pauls
Peter Brent Sampson
Original Assignee
University Health Network
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Priority claimed from PCT/CA2017/050848 external-priority patent/WO2018014116A1/en
Publication of NZ749844A publication Critical patent/NZ749844A/en
Publication of NZ749844B2 publication Critical patent/NZ749844B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds
    • C30B29/58Macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution

Abstract

The present invention relates to a novel co-crystal of the compound of formula (I): (Formula (I)) wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.

Claims (4)

1. A co-crystal of compound (I) and a co-former molecule, or a solvate of the co-crystal, wherein the co-former molecule is phosphoric acid.
2. The stal of claim 1, wherein the molar ratio of compound (I) : phosphoric acid in the co-crystal is 1:2.
3. The co-crystal of claim 1 or 2, wherein the co-crystal is a hydrate.
4. The co-crystal of any one of claims 1-3, wherein the molar ratio of nd (I) : phosphoric acid : H2O in the co-crystal is 1:2:
NZ749844A 2017-07-13 Solid forms of ttk inhibitor NZ749844B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662363424P 2016-07-18 2016-07-18
PCT/CA2017/050848 WO2018014116A1 (en) 2016-07-18 2017-07-13 Solid forms of ttk inhibitor

Publications (2)

Publication Number Publication Date
NZ749844A NZ749844A (en) 2024-03-22
NZ749844B2 true NZ749844B2 (en) 2024-06-25

Family

ID=

Similar Documents

Publication Publication Date Title
MX2021004431A (en) Novel processes.
PH12019502436A1 (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
MX2023003564A (en) Compounds and their use in treating cancer.
NZ777871A (en) Small molecule modulators of il-17
MX2008013212A (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors.
NZ708593A (en) Novel pyrazole derivative
MX2012012225A (en) Nitric oxide releasing prodrugs of therapeutic agents.
MX2022010520A (en) Peptide macrocycles against acinetobacter baumannii.
MX2009004908A (en) Chemical compounds.
UA86614C2 (en) Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine
NZ726366A (en) Syk inhibitors
MX2022006990A (en) Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA201992090A1 (en) Deuterated Imidazo [4,5-c] Quinolin-2-One Compounds and Their Use in Cancer Treatment
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2024014315A (en) Amido heteroaromatic compounds useful in the treatment of liver diseases
MX2009007889A (en) 3 - cinnolinecarboxamide derivatives and their use for treating cancer.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2021008658A (en) Solid forms of ttk inhibitor.
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
RU2010120806A (en) MONTELUKAST ACID INHALATION COMPOSITIONS AND PDE-4 INHIBITOR OR INHALATION CORTICOSTEROID
NZ749844B2 (en) Solid forms of ttk inhibitor